Short Interest in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Expands By 16.8%

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the target of a significant growth in short interest in November. As of November 15th, there was short interest totalling 89,600 shares, a growth of 16.8% from the October 31st total of 76,700 shares. Approximately 3.9% of the shares of the stock are sold short. Based on an average daily volume of 38,000 shares, the short-interest ratio is currently 2.4 days.

Cumberland Pharmaceuticals Trading Down 3.8 %

Shares of CPIX traded down $0.05 during trading hours on Tuesday, hitting $1.25. The company had a trading volume of 118,772 shares, compared to its average volume of 28,941. The firm has a market cap of $17.55 million, a P/E ratio of -1.62 and a beta of 0.30. The stock’s 50 day moving average price is $1.22 and its 200 day moving average price is $1.36. The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41. Cumberland Pharmaceuticals has a 52-week low of $1.04 and a 52-week high of $2.36.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Cumberland Pharmaceuticals in a research report on Tuesday, November 26th. They set a “hold” rating on the stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.